BR112022009754A2 - Derivados macrocíclicos de sulfonila como inibidores de mcl-1 - Google Patents

Derivados macrocíclicos de sulfonila como inibidores de mcl-1

Info

Publication number
BR112022009754A2
BR112022009754A2 BR112022009754A BR112022009754A BR112022009754A2 BR 112022009754 A2 BR112022009754 A2 BR 112022009754A2 BR 112022009754 A BR112022009754 A BR 112022009754A BR 112022009754 A BR112022009754 A BR 112022009754A BR 112022009754 A2 BR112022009754 A2 BR 112022009754A2
Authority
BR
Brazil
Prior art keywords
mcl
inhibitors
macrocyclic
sulphonyl derivatives
sulphonyl
Prior art date
Application number
BR112022009754A
Other languages
English (en)
Inventor
Jan Rita Rombouts Frederik
Christian Albert Ghislain De Boeck Benoit
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022009754A2 publication Critical patent/BR112022009754A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DERIVADOS MACROCÍCLICOS DE SULFONILA COMO INIBIDORES DE MCL-1. A presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia em um indivíduo, composição farmacêutica compreendendo tais compostos e ao seu uso como inibidores da MCL-1, úteis para tratar doenças como o câncer.
BR112022009754A 2019-11-21 2020-11-20 Derivados macrocíclicos de sulfonila como inibidores de mcl-1 BR112022009754A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19210714 2019-11-21
PCT/EP2020/082902 WO2021099580A1 (en) 2019-11-21 2020-11-20 Macrocyclic sulfonyl derivatives as mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
BR112022009754A2 true BR112022009754A2 (pt) 2022-08-09

Family

ID=68653383

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009754A BR112022009754A2 (pt) 2019-11-21 2020-11-20 Derivados macrocíclicos de sulfonila como inibidores de mcl-1

Country Status (10)

Country Link
US (1) US20230029194A1 (pt)
EP (1) EP4061820A1 (pt)
JP (1) JP2023502692A (pt)
KR (1) KR20220103985A (pt)
CN (1) CN114728986A (pt)
AU (1) AU2020388974A1 (pt)
BR (1) BR112022009754A2 (pt)
CA (1) CA3157590A1 (pt)
MX (1) MX2022006180A (pt)
WO (1) WO2021099580A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
ES2400371T3 (es) 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
PT2134685E (pt) 2007-04-16 2015-11-25 Abbvie Inc Derivados de índole não substituídos na posição 7 como inibidores de mcl-1
BRPI0810365A2 (pt) 2007-04-16 2014-10-29 Abbott Lab Inibidores de mlc-1 de indol 7-substituído
PT3445767T (pt) 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
EP3858840A4 (en) 2018-09-30 2022-05-04 Jiangsu Hengrui Medicine Co., Ltd. INDOL MACROCYCLIC DERIVATIVE, METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE
CN110845520B (zh) 2018-11-22 2021-04-13 苏州亚盛药业有限公司 作为mcl-1抑制剂的大环吲哚
CN112204036B (zh) 2019-01-23 2022-12-27 苏州亚盛药业有限公司 作为mcl-1抑制剂的大环稠合的吡唑
KR20210153051A (ko) 2019-03-08 2021-12-16 제노 매니지먼트, 인크. 매크로사이클릭 화합물

Also Published As

Publication number Publication date
JP2023502692A (ja) 2023-01-25
AU2020388974A1 (en) 2022-07-07
KR20220103985A (ko) 2022-07-25
EP4061820A1 (en) 2022-09-28
MX2022006180A (es) 2022-06-14
CN114728986A (zh) 2022-07-08
US20230029194A1 (en) 2023-01-26
WO2021099580A1 (en) 2021-05-27
CA3157590A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
GEP20217316B (en) Aromatic sulfonamide derivatives
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112023025738A2 (pt) Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
BR112022009754A2 (pt) Derivados macrocíclicos de sulfonila como inibidores de mcl-1
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
BR112018012307A2 (pt) derivados de pirrol[3,2-c]piridina-6-amino
BR112019025478A8 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer